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Background and purpose: Silymarin, a standardized extract of the milk thistle seeds,
has been widely used to treat chronic hepatitis, cirrhosis, and other types of toxic
liver damage. Despite increasing studies on the action of silymarin and its major active
constituent, silybin in their therapeutic properties against insulin resistance, diabetes and
hyperlipidaemia in vitro and in vivo, the mechanism underlying silymarin action remains
unclear.
Experimental approach: C57BL/6 mice were fed high-fat diet (HFD) for 3 months
to induce obesity, insulin resistance, hyperlipidaemia, and fatty liver. These mice were
then continuously treated with HFD alone or mixed with silymarin at 40 mg/100 g for
additional 6 weeks. Biochemical analysis was used to test the serum lipid and bile acid
profiles. Farnesyl X receptor (FXR) and nuclear factor kappa B (NF-κB) transactivities
were analyzed in liver using a gene reporter assay based on quantitative RT-PCR.
Key results: Silymarin treatment ameliorated insulin resistance, dyslipidaemia and
inflammation, and reconstituted the bile acid pool in liver of diet-induced obesity.
Associated with this, silybin and silymarin enhanced FXR transactivity. Consistently, in
HepG2 cells, silybin inhibited NF-κB signaling, which was enhanced by FXR activation.
Conclusion and implications: Our results suggest that silybin is an effective
component of silymarin for treating metabolic syndrome by stimulating FXR signaling.
Keywords: silymarin, silybin, metabolic syndrome, non-alcoholic fatty liver disease, farnesyl X receptor
Abbreviations: ALT, alanine aminotransferase; AST, aspartate transaminase; BA, bile acid; CA, cholic acid; DIO, diet-
induced obesity; DMSO, dimethylsulfoxide; FXR, farnesyl X receptor; HDL-c, high density lipoprotein cholesterol; HF,
high-fat; IPITT, intraperitoneal insulin tolerance test; LDL-c, low density lipoprotein cholesterol; NAFLD, non-alcoholic
fatty liver disease; NF-κB, nuclear factor kappa B; NR, nuclear receptor; MS, metabolic syndrome; Rosi, rosiglitazone; TBA,
total bile acid; TC, total cholesterol; TCA, taurocholic acid; TCDCA, tauro-chenodeoxycholic acid; TG, triglyceride; TUDCA,
tauro-ursodeoxycholic acid.
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INTRODUCTION
Metabolic syndrome encompasses a cluster of conditions
including obesity, type 2 diabetes, dyslipidaemia, atherosclerosis,
cardiovascular disease, NAFLD and hepatobiliary diseases
(Bonora, 2006; Rui, 2014). Because of rapid transition to over-
nutritious environment and concealed disease progression, MS
has become an epidemic and one leading killer worldwide
(Finucane et al., 2011; Wahi et al., 2011). Maintaining a lifestyle
with balanced energy metabolism is necessary to prevent but is
not sufficient to treat MS, suggesting a critical importance for
pharmacotherapy in treating and reversing MS. However, due
to its complex pathogenesis, there are few approved prescription
drugs that are able to effectively cure MS (Heal et al., 2009;
Douglas et al., 2013).
The farnesyl X receptor (FXR, Nr1h4) serves as an intracellular
BA-responsive ligand-activated NR (Makishima et al., 1999).
It is ubiquitous in all tissues but highly expressed in liver,
ileum, and adrenal gland (Matsubara et al., 2013). FXR has been
shown to play an essential role in controlling BA homeostasis
and protecting against liver injury resulting from cholestasis
or drug induction, as well as maintaining normal lipid and
glucose metabolism by regulating the expression of a series of
downstream target genes (Westin et al., 2005; Cariou et al.,
2006; Lee et al., 2006; Zhang et al., 2006, 2012; Kim et al.,
2007; Matsubara et al., 2013). FXR−/− mice have an array of
metabolic derangements including impaired glucose tolerance
and insulin sensitivity, increased plasma lipids levels, serious
NAFLD and liver damage, etc. (Kong et al., 2008; Lefebvre and
Staels, 2014). FXR is also reported to protect against toxic liver
damage, hepatitis, and cirrhosis (Liu et al., 2003; Yang et al.,
2007; Matsubara et al., 2013; Beuers et al., 2015). Targeting FXR
is considered as a promising avenue in the treatment of liver
diseases.
Inflammation is a complex biological response that is
involved in various diseases. It has been reported that the
FXR signal is involved in regulation of the inflammation
response (Arrese and Karpen, 2010; Gadaleta et al., 2011).
Antagonizing FXR can interact with NF-κB signaling leading to
exacerbation of inflammation (Wang et al., 2008). NF-κB as a
nuclear transcription factor directs the inflammatory response
by controlling the expression of genes involved in inflammation
(Hayden and Ghosh, 2008). In addition, numerous studies have
implicated the NF-κB inflammatory program in the development
of multiple metabolic diseases, and almost all liver diseases
accompany hepatic inflammation (Elsharkawy and Mann, 2007).
Interfering with NF-κB-driven inflammation could decrease
hyperglycaemia and insulin resistance in patients (Baker et al.,
2011).
In the US and Europe, about 65% of patients with liver
metabolic disorders take herbal medicine (Tindle et al., 2005).
Due to their apparent beneficial effects to human health,
treatments with natural herbal medicine for diverse chronic
MSs have become more and more popular (Stickel et al., 2002;
Corns, 2003; Adewusi and Afolayan, 2010; Salomone et al.,
2016). Silymarin is a natural herbal extraction from the fruit
and seeds of the Silybum marianum (Milk thistle), consisting of
seven flavonolignans (silybin A, silybin B, isosilybin A, isosilybin
B, silychristin, isosilychristin, and silydianin; Kvasnicˇka et al.,
2003; Abenavoli et al., 2010; Biedermann et al., 2014). Milk
thistle fruits and seeds have been used to treat liver and biliary
disorders for more than 2000 years (Saller et al., 2001; Hoofnagle,
2005; Tamayo and Diamond, 2007; Abenavoli et al., 2010).
Previous studies have proved that silymarin have antioxidant,
anti-inflammation and anti-cancer effect properties, and improve
homeostatic maintenance of glycaemia (Angulo et al., 2000;
Kidd and Head, 2005; Gazák et al., 2007; Loguercio et al.,
2012; Polyak et al., 2013). The flavonolignan silybin (a 1:1
mixture of silybin A and silybin B, which accounts for about
50–70% of the silymarin extract) is identified as the major
active ingredient in silymarin (Kvasnicˇka et al., 2003; Lee and
Liu, 2003). Silymarin is used in the treatment of toxic liver
damage, chronic hepatitis, and cirrhosis in some EU countries
and China (Saller et al., 2001). Although clinical practices
and animal experiments have repeatedly proven the effective
therapeutic roles of silymarin and silybin in vivo (Tamayo
and Diamond, 2007), the underlying molecular mechanism
remains largely unknown. In the past 10 years, the mechanistic
studies of silymarin and silybin were concentrated on reducing
the mitochondrial ROS generation, inhibiting glycogenolysis
and gluconeogenesis or blocking the activation of intrahepatic
NF-κB signal pathway (Velussi et al., 1997; Abenavoli et al.,
2010; Wu et al., 2011; Raina et al., 2013). No clear molecular
target of silymarin or silybin has been reported. Here we
identified silymarin and silybin as novel FXR agonists, and
found that silybin inhibited the NF-κB signal pathway via
negative crosstalk with the FXR in hepatocytes. In animal
experiments, we found silymarin attenuated hyperlipidaemia,
insulin resistance, and altered the composition of liver BAs
pool in HF diet-fed C57BL/6 mice. These therapeutic effects of
silymarin in vivo may be linked to the regulation of FXR and NF-
κB signaling pathways by silybin, the major active constituent in
silymarin.
MATERIALS AND METHODS
Chemicals and Diets
Silymarin (Legalon, Madaus, German) powder was dissolved
in dimethylsulfoxide to the final concentration of 40 mg/ml
for cell culture. Silybin, GW4064, T090173, Rosiglitazone, int-
777, WY14643, rifampicin, TNFα, and all of the BAs standard
references mentioned in this article were purchased from Sigma–
Aldrich (St. Louis, MO, USA). HF diets (60% of calories derived
from fat), and low-calorie diets (10% of calories derived from
fat) were purchased from Research Diet (D12492, D12450B, New
Brunswick, NJ, USA).
Cell Culture and Treatment
HepG2 (ATCC) cells were seeded on six-well plates (1 × 106
cells/well) and grown to 80% confluence with high-glucose
DMEM containing 10% FBS at 37◦C in 5% CO2. The following
day, cells were treated with vehicle control, silymarin (40 µg/ml)
or silybin (25 µM). After 18-h treatment, the cells were treated
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with or without TNFα (10 ng/mL) and then collected for RNA
isolation after 6-h incubation.
Transient Transfection of Cultured Cells
and Reporter Assays
The reporter assay was performed using the Dual-Luciferase
Reporter Assay System (Promega, USA) as previously described
(Huang et al., 2006). For NR transcription activity assay, the
expression plasmids for phFXR, phRXR and FXR-dependent
reporter (EcRE-LUC), pCMXGal-hPPARα, γ, LXRα, β, and PXR-
LBD and the Gal4 reporter vector MH100 × 4-TK-Luc were
co-transfected with a reporter construct so that 1 µg of the
relevant plasmid combined with 1 µg of reporter plasmids and
0.1 µg of pREP7 (Renilla luciferase) reporter could be used
to normalize transfection efficiencies. The transfection mixture,
which contained 10 µg of total plasmids and 15 µl FuGENE-HD
(Roche) per ml of DMEM, was added to HEK293T cells (ATCC)
for 24 h and then removed. The FXR, PPARα, PPARγ, LXRs, and
PXR agonists (GW4064, WY14643, Rosiglitazone, T090173, and
Rifampicin, respectively), silymarin or silybin were added to fresh
media and the cells were incubated for another 24 h to determine
luciferase activity.
To characterize NF-κB activity, HepG2 cells were co-
transfected with p65 expression vector, NF-κBx3-LUC, control
plasmid pREP7, and/or FXR/RXR expression plasmids using
FuGENE-HD. After 24 h, cells were pre-treated with the control,
silymarin, or silybin for 18 h before treatment with TNFα
(10 ng/mL) for 6 h. Subsequently, cells were collected and
subjected to luciferase activity analysis. To determine the level
of hTGR5 activation, hTGR5 expression plasmid and luciferase
reporter pCRE-Luc and pREP7 were transiently transfected into
HEK293T cells for 24 h. Then cells were incubated with the
control, silymarin (40 µg/ml), or silybin (50 µM) for another
day before being used for reporter assay. The renilla luciferase
activity was assayed to normalize transfection efficiencies. All of
the transfection experiments were performed in triplicate and
repeated at least three times independently.
Animal Experiment
All animal protocols used in this study were approved by
Shanghai University of Traditional Chinese Medicine (Approval
Number: SZY20150524). Female C57BL/6 mice were purchased
from the SLAC Laboratory (Shanghai, China). Animals were
housed and bred according to standardized procedures, under
controlled temperature (22–23◦C) and on a 12-h light, 12-h
dark cycle. Six-week-old female mice were fed with HF diet for
12 weeks to induce obesity and these mice were then randomly
divided into three groups according to body weight: Chow
group (10% of calories derived from fat), HF group (HF, 60%
of calories derived from fat), and Silymarin group (HF diet
supplemented with silymarin powder, Legalon from MADAUS
GmbH, Germany, at dose of 40 mg/100 g diet). Mice were treated
for additional 6 weeks. Food intake amount was measured by
recording food weight every 2 days throughout the experiment.
The amount of food intake over a 24-h period was calculated.
Intraperitoneal Glucose Tolerance and
Insulin Tolerance
At the end of the treatment, mice were fasted overnight (12 h).
The baseline glucose values (0 min), prior to the injection of
glucose (1 g/kg body weight), were measured through tail vein.
Additional blood samples were collected at regular intervals (15,
30, 60, and 90 min) during glucose tolerance tests. For the
IPITT, non-fasted glucose levels were determined from the tail
vein (0 min). Then insulin (Sigma, St. Louis, MO, USA) was
injected intraperitoneally (0.75 U/kg body weight). Subsequent
blood samples were taken at 15, 30, 60, 90, and 120 min after
insulin administration for glucose measurement.
Serum Chemistry Analysis
At the end of animal experiment study, mice were anesthetized
20% urethane (Sigma, St. Louis, MO, USA) and cardiac blood
was taken. Levels of serum alanine aminotransferase, AST, TG,
TC, HDL-c, and LDL-c were measured using a Hitachi 7020
Automatic Analyzer (Hitachi, Limited, Tokyo, Japan) with 100 µl
of heart blood serum.
Histochemistry
Liver tissues were fixed in formalin, and paraffin-embedded
sections were cut at 5 µm. Sections were stained with
haematoxylin and eosin according to a standard procedure.
Hepatic Lipid Content Analysis
Lipid content was measured as described (Folch et al., 1957).
Briefly, liver tissues (100 mg) were homogenized with 2 ml
chloroform-methanol and then agitated overnight on an orbital
shaker at 4◦C. The homogenate was then centrifuged (5 min at
5,000 rpm), 0.9% NaCl solution was subsequently added to the
liquid phase before the samples were vortexed. Phase separation
was induced by centrifugation (2,000 rpm for 10 min), and the
bottom phase was removed to a new tube and evaporated to
dryness, Samples were then resuspended in 500 µl chloroform-
1% Triton X-100, evaporated to dryness, and finally resuspended
in 500 µl of water. The quantities of total cholesterol and
triglycerides (KINGHA WK, China) in liver lipid extracts
were then assayed by using enzymatic kits according to the
manufacturers’ protocols.
RNA Extraction and Quantitative PCR
Total RNA from HepG2 cells or mouse livers was isolated
using the TRIzol method (Invitrogen, Carlsbad, CA, USA).
The first-strand cDNA was synthesized with a cDNA synthesis
kit (Fermentas, Madison, WI, USA). Quantitative real-time
polymerase chain reaction (PCR) was carried out using SYBR
green PCR Mastermix. The results were analyzed on an ABI
StepOnePlus real-time PCR system (Applied Biosystems, USA).
Values were normalized to Beta-actin. Sequences for primers are
listed in Tables 1 and 2.
Quantification of BAs in Mice
Measurement of TBAs in mouse livers and feces was performed
as the following. Livers were weighed and homogenized in
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TABLE 1 | Sequences of the human primers used in real time polymerase chain reaction (PCR).
Gene Sense primer Anti-sense primer
NR1H4 ATGGGAATGTTGGCTGAATG CCTGCATGACTTTGTTGTCG
NR0B2 AGGCCTCCAAGCCGCCTCCCACATTGGGC GCAGGCTGGTCGGAAACTTGAGGGT
LRH1 CTAGAAGCTGTAAGGGCCGACCG TCCATTGGCTCGGATGAGGGCT
SULT2A1 AACAGGACACAGGAAGAACCAT CAGTCCCCAGATACACCTTTTC
ABCC2 TCGGAATGTGAATAGCCTGAAG CGCAAGGATGATGAAGAATATCG
ABCB4 GCAGACGGTGGCCCTGGTTGG TGGAAAACAGCACCGGCTCCTG
APOC2 GAGATGCCTAGCCCGACCTTCCTCAC GCTCAGTCTGAACCTGGGGGATCAGG
CYP7A1 GAGAAGGCAAACGGGTGAAC AGCACAGCCCAGGTATGGA
CYP8B1 CCCTCTTTCCCTACCTCTCAGT AAGTGTGTGACCATAAGCAGGA
PPARα GAAATGGGAAACATCCAAGAGA CACAGGATAAGTCACCGAGGA
ACOX1 CCAAGCTTTCCTGCTCAGTGTT CCCCCAGTCCCTTTTCTTCA
CPT1α TGGCGTCTGAGAAGCATCAGCATA ACACCACGTAAAGGCAGAAGAGGT
ACC GGATGGTGTTCACTCGGTAATAGA GGGTGATATGTGCTGCGTCAT
β-ACTIN AATCTGGCACCACACCTTCTA ATAGCACAGCCTGGATAGCAAC
TABLE 2 | Sequences of the mouse primers used in real time PCR.
Gene Sense primer Anti-sense primer
β-actin TGTCCACCTTCCAGCAGATGT AGCTCAGTAACAGTCCGCCTAGA
Nr1h4 TTCCTCAAGTTCAGCCACAG TCGCCTGAGTTCATAGATGC
Nr0b2 GGAGTCTTTCTGGAGCCTTG ATCTGGGTTGAAGAGGATCG
Lrh1 TCAGTTCGATCAGCGGGAGTTTGT TGCAGGTTCTCCAGGTTCTTCACA
Hnf4α GTGCTTCCGGGCTGGCATGAA AGGTGATCTGCTGGGACAGAACC
Pparα AGGCTGTAAGGGCTTCTTTCG GGCATTTGTTCCGGTTCTTC
Pparβ AGTGACCTGGCGCTCTTCAT CGCAGAATGGTGTCCTGGAT
Pparγ CGCTGATGCACTGCCTATGA AGAGGTCCACAGAGCTGATTCC
Pgc1α TGTTCCCGATCACCATATTCC GGTGTCTGTAGTGGCTTGATTC
Pgc1β GGGTGCGCCTCCAAGTG TCTACAGACAGAAGATGTTATGTGAACAC
G6pc GTGGCAGTGGTCGGAGACT ACGGGCGTTGTCCAAAC
Pck1 CACCATCACCTCCTGGAAGA GGGTGCAGAATCTCGAGTTG
Apoc2 TGATGTTGGGAAATGAGG ATCGGGTATGTCTTCTGGTA
Apoai ACTCGGGACTTCTGGGATA AGTGTCTTCAGGTGGGTTTT
Acc GAATCTCCTGGTGACAATGCTTATT GGTCTTGCTGAGTTGGGTTAGCT
Scd1 CTTATCATTGCCAACACCA CTTCTCGGCTTTCAGGTC
Tnfα ATGGATCTCAAAGACAACCAACTAG ACGGCAGAGAGGAGGTTGACTT
Mcp-1 AGGTCCCTGTCATGCTTC GTGCTTGAGGTGGTTGTG
Il1β TCGTGCTGTCGGACCCATAT GGTTCTCCTTGTACAAAGCTCATG
Cox2 TGAGCAACTATTCCAAACCAGC GCACGTAGTCTTCGATCACTATC
Cyp7a1 TGATCCTCTGGGCATCTCAAGCAA AGCTCTTGGCCAGCACTCTGTAAT
Cyp8b1 GGACAGCCTATCCTTGGTGA GACGGAACTTCCTGAACAGC
Cyp27a1 GAGAGTGAATCAGGGGACCA CCATTTGGGAAGGAAAGTGA
Ntcp TATCAGCCCCCTTCAATTTC GTGAGCCTTGATCTTGCTGA
Baat CCATTGAAAAAGCTCATGGA ATCAGCTGTGCTATGGCTTG
Bacs GATGCCCTTGCTACACTCT AGGACAAGCCCTATCGTAT
Abcb11 CGGACCTGTATTGTCATTGC CCCTTCTGGTCCATCAGTTT
10X volume water. TBA level determination was performed
on homogenate samples using the TBA Measurement Kit
(KeHua, China) after quantification of intracellular protein
concentration. The TBA levels were normalized to intracellular
protein content. Protein concentrations were determined by
BCA protein assay kit (Sigma, St. Louis, MO, USA). The
fecal TBA analysis was performed as the same method
described above and calculated by normalizing the feces
weight.
To measure hepatic BA pool size and composition, liver-
tissue samples were weighed, and TBA was extracted in 5X
volumes of acetonitrile followed by centrifugation at 14,300 rpm
for 10 min. The supernatant was dried under nitrogen steam
before re-dissolved in methanol solution (methanol:water:formic
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acid = 50:50:0.01) and then subject to centrifugation at
14,300 rpm for 10 min. Supernatant bile salt species were
analyzed by ultra-performance liquid chromatography (UPLC)
triple time of flight/MS analysis (UPLC-MS, Waters Co., MA,
USA). The relevant parameters were described in a previous
publication (Yang et al., 2012).
Molecular Docking
The crystal structure of NR FXR (PDB code 1OT7) was retrieved
from the Research Collaboratory for Structural Bioinformatics
(RCSB) protein data bank. Silybin A and silybin B were
constructed using the sketcher module in Sybyl and their
minimum energy conformations were calculated using the
Minimize module of Sybyl. The force field was Tripos with an 8 Å
cutoff for non-bonded interactions, and the atomic point charges
were also calculated with Gasteiger-Huckel. Minimizations
were achieved using the steepest descent method for the first
100 steps, followed by the Broyden-Fletcher-Goldfarb-Shanno
(BFGS) method until the root-mean-square (RMS) of the
gradient became<0.005 kcal/(mol·Å). The Surflex-Dock module
implemented in the Sybyl program was used for the docking
studies. The obeticholic acid binding pocket of FXR was used
for the docking simulation. Both silybin A and silybin B were
docked into the binding site by an empirical scoring function
and a patented search engine in Surflex-Dock, applied with the
automatic docking. Other parameters were established by default
in the software.
Statistical Analysis
All values were expressed as means ± SEM and analyzed using
the statistical package for the social science (SPSS, version 15.0).
Paired or unpaired two tailed t-tests were used to detect difference
FIGURE 1 | Silybin and silymarin activate FXR transactivity in vitro. (A,B) Structure of Silybin A and Silybin B. Silybin (C) and silymarin (D) activate FXR
transactivity. HEK293T cells were co-transfected with phFXR, phRXR expression plasmids, and FXR-dependent reporter (EcRE-LUC) for 24 h and treated with the
FXR agonist GW4064 (10 µM), control (DMSO), silybin (1.5, 3, 6, 12, 25, 50 µM) and silymarin (10, 20, and 40 µg/ml) for another 24 h. The relative luciferase
activities (RLU) were measured by comparison to renilla luciferase activities. (E,F) The relative gene expression levels in silybin-treated (25 µM) and control (DMSO)
HepG2 cells. Beta-ACTIN was used as an internal control for normalizing the mRNA levels. The results represent three independent experiments, and data are
presented as means ± SEM. (n = 3). ∗P < 0.05 vs. HEK293T or HepG2 control.
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in the mean values of treatment group and control and analysis
of variance (ANOVA) for the difference among more than two
groups. Differences with P values <0.05 were considered to be
statistically significant.
RESULTS
Silymarin and Silybin Stimulate FXR
Transactivity In vitro
To test whether silymarin and its major constituent silybin
(silybin A:B = 1:1, Figures 1A,B) are able to activate FXR,
we performed a gene reporter assay by co-transfected hFXR,
hRXR expression vectors, and FXR-dependent reporter (EcRE-
LUC) into HEK293T cells. The results demonstrated that silybin
activated the FXR transactivity in a dose-dependent manner
(Figure 1C). Silymarin showed similar effects but with lower
activity in (Figure 1D). We also analyzed the effects of silybin
and silymarin on other important NR transactivity and the results
showed that there were no effects of silybin or silymarin on PXR,
PPARγ, α, β/δ, and LXRα, β transactivities (data not shown),
suggesting that the silybin activates FXR specifically.
Farnesyl X receptor agonists have been shown to activate a
series of target genes. We therefore examined whether silybin
could regulate known target gene expression in HepG2 cells. As
expected, silybin treatment induced FXR target gene expression
when compared with mock control groups (Figures 1E,F),
suggesting an increased FXR transactivity by silybin.
TGR5, abile acid sensitive G-protein coupled receptor, has
been reported to bind with diverse FXR agonists (Chen et al.,
2011; Keitel and Häussinger, 2012). To clarify whether silybin
and silymarin also activate TGR5-cAMP signaling, we transiently
transfected hTGR5 expression plasmid and pCRE-Luc reporter
into HEK293T cells over a period of 24 h. Even with a high dose
(Silybin at 50 µM and silymarin at 40 µg/ml), neither silybin
nor silymarin stimulated the pCRE-Luc reporter signaling (data
not shown), indicating that both drugs have limited influence on
activating hTGR5.
Silybin Interacts with FXR
To further test potential direct interaction between silybin and
NR FXR, the structure of the complex of FXR and silybin was
analyzed by molecular docking. The obeticholic acid binding site
of FXR has been validated as the binding pocket of silybin. Both
silybin A and silybin B were docked into the binding pocket,
the pose that ranked first complex with NR FXR were shown in
Figures 2A,C. Silybin skeleton was surrounded by a hydrophobic
pocket composed of Arg261, Met262, Leu284, Met287, Ala288,
His291, Ile294, Met325, Arg328, Ser329, Ile332, Phe333, Leu345,
Ile349, Phe363, and Tyr366, where van der Waals forces play
FIGURE 2 | Silybin interacts with FXR. (A) The structure of the complex of the FXR and Silybin A by molecular docking. (B) The interaction map of the complex of
the FXR and silybin A in the binding site. (C) The structure of the complex of the FXR and silybin B by molecular docking. (D) The interaction map of the complex of
the FXR and silybin B in the binding site.
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a dominant role in the interactions. These interactions were
postulated to be the primary reason for silybin activity. The
specific interaction of silybin A and silybin B with FXR is
also displayed in Figures 2B,D. Hydrogen-bonding interactions
showed that silybin A was bound to Arg261 and Arg328 of
subunit A of FXR, while silybin B is bound to Arg328 and Tyr366
of subunit A of FXR. These H-bonds help to enhance the binding
stability.
Silymarin Exerts Hypoglycaemic Effects
in DIO Mice
To test whether silymarin affects glucose homeostasis, obese
C57BL/6 mice fed HFD were divided in two groups, one
continued to feed on a HF diet as control and the other fed
HF diet mixed with silymarin (100 mg Legalon or 40 mg
silymarin/100 g diet) for additional 6 weeks. Silymarin treatment
significantly ameliorated fasting glucose (Figure 3C), glucose
intolerance at 30 and 60 min (Figure 3D), and insulin tolerance
in obese mice at 15, 60, and 120 min (Figure 3E) without
changes in body weight gain or food intake (Figures 3A,B),
suggesting that silymarin improves glucose homeostasis in DIO
mice.
Silymarin Attenuates Dyslipidaemia in
DIO Mice
We next assayed the lipid profile in the diet-induced obese mice.
As expected, HF diet feeding elevated serum TC, HDL-c, and
LDL-c levels in HF-fed control mice compared to Chow controls
(Figure 4A), and notably, 6-week silymarin treatment decreased
serum LDL-c levels in DIO mice (Figure 4A), but not TG, TC,
and HDL-c. OCA and other FXR agonists have been identified to
have therapeutic effects against NFALD and NASH. We therefore
determined whether silymarin could improve hepatic steatosis.
The HE staining results showed that silymarin treatment did
not significantly reduce hepatic steatosis (Figure 4B), and this
was confirmed by lipid content measurement, which showed
no notably reduction when compared to HF-fed controls
(Figures 4C,D). Serum ALT and AST levels were markedly higher
in DIO mice compared to control mice, but no difference in ALT
or AST levels were found between DIO controls and silymarin-
treated mice (Figures 4E,F). Subsequent gene expression analysis
(Figure 4G) indicated that silymarin markedly decreased mRNAs
of Srebp2 and Hmgcr, two genes involved in cholesterol
metabolism in DIO mice. Collectively, these results suggest that
silymarin corrects the serum dyslipidaemia in DIO mice.
FIGURE 3 | Silymarin improves blood glucose homeostasis in DIO C57BL/6 mice. (A) Body weight during the 6-week treatment. (B) Food intake amount.
(C) Fasting blood glucose level. (D) Glucose tolerance test (GTT). The mice were fasted overnight, and glucose were intraperitoneally injected (1 g of/kg body weight)
and blood glucose levels were determined at the indicated time points. (E) Insulin tolerance test (ITT). The non-fasted mice were intraperitoneally injected with insulin
(0.75 U/kg body weight) and blood glucose levels were determined. Data are presented as means ± SEM (n = 7). ∗P < 0.05, vs. Chow or HF group, NS, No
significance.
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FIGURE 4 | Silymarin ameliorates dyslipidemia in DIO mice. (A) Serum TC, TG, LDL-c, HDL-c. (B) H&E staining of liver sections (×200). (C) Liver TG level.
(D) Liver TC level. (E) Serum ALT level. (F) Serum AST level. (G) The relative gene expression levels in the livers. Beta-Actin was used as an internal control for
normalizing the mRNA levels. Data are presented as means ± SEM (n = 7). ∗P < 0.05, vs. Chow or HF group, NS, No significance.
Silymarin Alters BA Composition In vivo
The central function of FXR is to regulate BA homeostasis.
Therefore, TBAs in livers and feces were determined following
analysis of hepatic BA composition. After silymarin treatment,
DIO mice showed markedly decreased TBA levels in
feces and a tendency, although not statistically significant,
toward a decreased level in liver, compared with HF controls
(Figures 5B,C). Meanwhile, the composition of hepatic BA was
also altered by silymarin treating. In contrast to high fat diet fed
mice, silymarin treatment strikingly decreased fraction of TCA,
murine taurocholic acid (mTCA), TCDCA, and TUDCA, which
was accompanied with an increasing fraction of the α,β murine
taurocholic acid (α,β mTCA), and CA in silymarin-treated
DIO mice (Figure 5A; Table 3). Moreover, gene expression
experiments showed that a series of genes such as Cyp7a1,
Cyp8b1, Ntcp, Baat, Bacs, and Abcb11 were markedly decreased
in the silymarin treatment group as compared to HF controls
(Figure 5D). These data suggested silymarin contributes to
the changes of BA metabolism via influencing the BA signal
pathway.
Silymarin Mediates the Hepatic FXR
Signaling and Alleviates Inflammation
As a major organ tissue delivering FXR signals, the liver is
involved in diverse metabolic physiological functions as well
as the regulation of inflammation. We further address whether
silymarin mediates signaling downstream of FXR in the liver.
We compared the expression levels of a cluster of FXR target
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FIGURE 5 | Silymarin alters BA composition in DIO mice. (A) Hepatic TBA level. (B) Fecal TBA level. (C) Hepatic BA composition. (D) The relative gene
expression levels in the livers. Beta-Actin was used as an internal control for normalizing the mRNA levels. Data are presented as means ± SEM (n = 7). ∗P < 0.05,
vs. HF group, NS, No significance.
genes in the liver tissues between HF control mice and HF
supplemented silymarin group mice using quantitative RT-PCR.
Liver samples from silymarin-treated mice displayed significantly
lower expression levels of Nr1h4, Nr0b2, Lrh1, G6pc, Pck1, and
Apoc2 as well as inflammatory cytokine Cox2 while Pgc1β levels
were significantly higher (Figures 6A–C). These results suggest
that silymarin is able to alter hepatic FXR signaling and therefore
modulates its downstream targets related to gluconeogenesis,
lipogenesis, and inflammation in DIO mouse livers.
Silymarin and Silybin Inhibit NF-κB
Signaling Associated with FXR Activation
To test potential inhibitory effect on NF-κB pathway by silybin
and silymarin in vitro, HepG2 cells over-expressing p65 and
NF-κBx3-Luc were pre-treated with silybin and silymarin at
the indicated different concentrates, in a condition with an
enhanced NF-κB reporter activity by TNFα stimulation. Our
results (Figures 7A,B) showed that silybin (25 and 50 µM)
and silymarin (20 and 40 µg/ml) suppressed the NF-κB
transactivity induced by TNFα in HepG2 cells. Silybin (25 µM)
significantly reduced the levels of TNFα-induced expression
of TNFα, COX2, and MCP-1 mRNA as compared to vehicle
TABLE 3 | Hepatic BAs composition (%) in DIO mice.
BA HF Silymarin
T-MCA 11.24 6.22
T-CA 67.32 54.91
T-DCA 6.74 7.25
T-CDCA 2.54 1.31
T-HDCA 0.38 0.09
T-UDCA 2.02 1.07
HDCA 1.39 1.75
UDCA 2.18 2.87
LCA 0.05 0.35
DCA 0.35 0.53
CDCA 2.44 3.22
CA 1.46 3.13
βMCA 4.04 9.43
αMCA 2.17 4.07
(Figure 7C). FXR agonists such as GW4064 and 6ECDCA
were reported to inhibit NF-κB activity via FXR activation
(Wang et al., 2008). To test whether silybin and silymarin
have similar effects, we pre-treated HepG2 cells with silybin
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FIGURE 6 | Silymarin regulates FXR signal and alleviates the inflammation in DIO mice liver. The mRNA levels of NRs (A), glucose and lipid metabolism
related genes (B), and inflammation metabolism related genes (C) in the livers. Beta-actin was used as an internal control for normalizing the mRNA levels. Data are
presented as means ± SEM (n = 7). ∗P < 0.05, vs. HF group.
and silymarin prior to TNFα treatments. Silybin (50 µM)
and silymarin (40 µg/ml) weakened NF-κB signaling in the
condition with p65/NF-κBx3-Luc transfection alone. Meanwhile,
the transfection of these cells with p65/NF-κBx3-Luc plus
FXR/RXR inhibited NF-κB activity in the absence of exogenous
drug (Figures 7D,E). Furthermore, addition of silybin to HepG2
cells with FXR/RXR overexpression showed an augmented
suppressing effects, resulting in significant depression on NF-
κB activity (Figures 7D,E). These results indicate that silybin
and silymarin may strengthen interference with NF-κB activity
correlated with the activation of FXR.
DISCUSSION
In the present study, we provided evidence showing that silybin
and silymarin activated NR FXR and triggered a negatively
crosstalk with NF-κB. We also confirmed that silymarin can
be used to treat MS, especially to ameliorate hyperglycaemia,
dyslipidaemia, and regulate BA homeostasis in DIO mice. These
effects were probably achieved via the stimulation of FXR
signaling and suppression of NF-κB responses. Our data support
the possibility to use silybin as a novel natural FXR agonist that
can effectively treat and cure MD.
Previous studies have confirmed that silybin represents about
50–70% bioactive compounds in the silymarin extract (Kim
et al., 2003; Loguercio and Festi, 2011). FXR is an important
molecular target that can be used to control hepatobiliary diseases
of enterohepatic cycling, which has prompted the idea that
silybin might be correlated with FXR (Matsubara et al., 2013).
As expected, FXR gene reporter assay revealed that silybin and
silymarin apparently activated FXR reporter signal in a dose
dependent manner, which was proved by the change of mRNA
levels of FXR downstream target genes in HepG2 cells, including
increased expressions of NR0B2, SULT2A1, ABCC2, APOC2, and
PPARα, but decreased expression of CYP7A1. The molecular
docking assay further supported a direct binding between silybin
and FXR. These data support that silybin and silymarin are
capable of enhancing the FXR transactivity. These results suggest
that silybin is a potential agonist of FXR.
Farnesyl X receptor activation leading to improving lipid and
glucose metabolism has received a particularly intense attention.
Fasted FXR-null mice exhibit impaired glucose intolerance,
insulin insensitivity, and increased levels of plasma triglyceride,
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FIGURE 7 | Silymarin and silybin inhibit NF-κB signaling via activating FXR. Silybin (A) and silymarin (B) repressed NF-κB transactivity in HepG2 cells. HepG2
cells were co-transfected with the NF-κB reporter plasmids and P65 expression plasmids for 24 h and pretreated with the control (DMSO), silybin (12, 25, 50 µM)or
silymarin (10, 20, and 40 µg/ml) for 18 h before treatment with TNFα (10 ng/mL) for another 6 h. The RLU were measured by comparison to renilla luciferase
activities. ∗P < 0.05 compared to the groups of TNFα (n = 3). (C) The relative gene expression levels in silybin-treated (25 µM) and control (DMSO) HepG2 cells
incubated with TNFα (10 ng/mL). Beta-actin was used as an internal control for normalizing the mRNA levels. ∗P < 0.05 compared to the groups of TNFα or controls
(n = 3). Silybin (D) and silymarin (E) enhanced the inhibition of NF-κB signaling via activating FXR. HepG2 cells were co-transfected with the NF-κB reporter
plasmids and P65 expression plasmids with or without FXR/RXR expression plasmids before treatment with control (DMSO), TNFα (10 ng/mL), silybin (12 and
50 µM), or silymarin (10 and 40 µg/ml) according to (A,B). RLU were measured by comparison to renilla luciferase activities. ∗P < 0.05 vs. the groups of TNFα
(n = 3). The results represent three independent experiments, and data are presented as means ± SEM. NS, No significance.
free fatty acids, and cholesterol (Sinal et al., 2000; Zhang et al.,
2006; Cipriani et al., 2010; Prawitt et al., 2011). Treatment with
FXR agonists, GW4064, or INT-747, has been shown to reduce
plasma triglyceride, glucose levels, and improve insulin sensitivity
in several models of obesity and diabetes (Zhang et al., 2006;
Mason et al., 2010). These phenotypes have been attributed to
the ability of FXR to control the expression of several genes
involved in glycolipid metabolism. In our study, we also found
that silymarin treatment effectively lowered HF diet-induced
hyperglycaemia and insulin resistance in DIO mice, similarly
to the previous reports (Kazazis et al., 2014; Voroneanu et al.,
2016). Furthermore, gene expression analysis has demonstrated
down-regulation in the expression of certain genes, including
Pgc1α, G6pc, and Pck1, in silymarin-treated mice, suggesting
effective inhibition of hepatic gluconeogenesis, which could
explain the anti-diabetic efficacy of silymarin. Interestingly, these
gene changes were reminiscent of recent findings that FXR
activation downregulates the gluconeogenic program.
Previous reports showed that silymarin may be able to alleviate
hepatic steatosis (Ni and Wang, 2016). However, we did not
observe an improvement of the morphology in the liver of DIO
mice. This probably caused by the shorter phase of treatment in
our study. Extension of the treatment may result in better result
in morphology of the liver tissues.
It is well established that the inflammation response is
positively correlated with IR and diabetes (Baker et al., 2011).
Recently, silybin and silymarin were repeatedly reported to
be able to block inflammatory reactions in multifarious cells
via antagonizing transcription factor NF-κB (Bremner and
Heinrich, 2002; Dhanalakshmi et al., 2002; Salamone et al.,
2012). Consistently, we obtained similar results showing that
silybin and silymarin inhibited the TNFα-induced NF-κB signal
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in HepG2 cells as well as reducing TNFα, COX2, and MCP1
expression levels stimulated by TNFα in human hepatocytes.
These inflammatory cytokines are all shown to be directly
regulated by NF-κB (Baker et al., 2011). Notably, it is unknown
whether silybin interacts with NF-κB, i.e., the mechanism
underlying silybin control of NF-κB remains to be elucidated.
The anti-inflammatory effects of FXR have been well documented
(Shaik et al., 2015). An FXR agonist has been reported to
activate anti-inflammation responses via negatively regulation
of NF-κB (Wang et al., 2008). Deficiency of FXR was also
found to increase the development of liver and intestine
cancer via the upregulation of inflammation (Yang et al.,
2007). In the present study, we found that NF-κB activity was
largely inhibited in HepG2 cells transfected with FXR/RXR in
the absence of xenobiotics. We found that silybin treatment,
significantly enhanced the inhibitory effect on NF-κB activitys,
compared to the treatment condition without FXR/RXR. Silybin
suppressed NF-κB transactivity without FXR/RXR transfection.
Furthermore, the inhibitory efficiency of silybin on the NF-
κB reporter was increased by nearly 20% in HepG2 cells with
FXR/RXR overexpression. This suggests that suppression of NF-
κB transactivity by silybin may be correlated with the activation
level of FXR signaling. That silymarin treatment notably lowered
Cox2 gene expression in the liver of DIO mice also supported
the anti-inflammation action of silymarin in vivo. Our data
suggested that reduced hepatic inflammation signal in DIO mice
by silymarin may contribute to the antidiabetic effect.
Farnesyl X receptor is a key modulator of BA metabolism
in the enterohepatic system that acts via various feedforward
and feedback loops. FXR deficiency impairs BA homeostasis
(Matsubara et al., 2013). After a 6-week treatment, the hepatic
and fecal TBA levels in silymarin-treated mice were lower
than in HF controls, indicating a decreased BA pool size. In
addition, decreased proportions of TCA, mTCA, TCDCA, and
TUDCA with increased fraction of (α, β mTCA) and CA in
silymarin-treated mice compared to HF controls showed an
altered hepatic BA composition. Hepatic Lrh1, Ntcp, Cyp7a1,
and Cyp8b1 are essential genes in enterohepatic BA metabolism
and negatively regulated by FXR activation, which respectively,
promotes BA gene expression, uptakes of conjugated BAs,
controls BA synthesis and BA hydroxylation. Consistent with
the characteristics of reported FXR agonists, silymarin markedly
reduced Lrh1, Ntcp, Cyp7a1, and Cyp8b1 gene expression levels
in DIO mice, indicating that FXR is able to activate the
feedback loop of FXR signaling in liver tissue of the mice. This
finding further supports that silymarin is a natural FXR agonist
modulating BA homeostasis.
One complicating factor in the study of FXR biology is that
BAs are also ligands for multiple other receptors controlling MS
(Sinal et al., 2000). Here we excluded the agonist activity of
silybin on activating several important BA-related receptors such
as PPARα, γ, LXRα, β, PXR, and TGR5 in vitro via reporter assays.
However, we found that silymarin elevated the proportions of
LCA, (α, β mTCA), and CA in vivo. All of these compounds are
endogenous ligands for TGR5, which indicates that endogenous
TGR5 activation by several BAs might mediate partial silymarin
therapeutic effects.
CONCLUSION
we found that both silybin and silymarin stimulated FXR
transactivity and inhibited NF-κB signaling in vitro. Silmarin
supplementation ameliorated insulin resistance, hyperlipidaemia
and inflammation progress, and reconstituted the BA pool in
DIO mice. Our data suggest that the effects of silymarin on
metabolic disorders may be related to FXR activation and NF-κB
inhibition and that the majority of these effects are mediated by
its main active compound, silybin. Whether FXR is involved in
the treatment of silymarin for toxic liver damage, hepatitis, and
cirrhosis warrants further studies.
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